A newly developed vaccine for glioblastoma shows 'remarkable' promise, according to preliminary results from a study of the treatment. Patients with the disease typically die within 2 years. Some in the trial have now lived as long as 7 years.
A newly developed vaccine for glioblastoma shows 'remarkable' promise, according to preliminary results from a study of the treatment. Patients with the disease typically die within 2 years. Some in the trial have now lived as long as 7 years. Evan Vucci AP
A newly developed vaccine for glioblastoma shows 'remarkable' promise, according to preliminary results from a study of the treatment. Patients with the disease typically die within 2 years. Some in the trial have now lived as long as 7 years. Evan Vucci AP